COMPANY PROFILE

Vasopharm

Explore full profile

Biopharmaceutical company developing treatments for traumatic brain injuries

Würzburg, GermanyFounded 1998Biotech & Life Sciences

Valuation $50–100M Last recorded · 2019

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Vasopharm

Vasopharm, which now operates as veriNOS Pharmaceuticals, is a biopharmaceutical company that specializes in the research and development of treatments for cerebrovascular and cardiovascular diseases. The company is focused on developing small molecule therapeutics for the treatment of Traumatic Brain Injury (TBI). Its lead drug candidate is VAS203 (Ronopterin), a nitric oxide synthase inhibitor that has been investigated in clinical trials for its potential to improve outcomes in TBI patients.

The company's business model is centered on drug development, from discovery through to clinical trials and potential commercialization. Vasopharm was founded in 1998 as a spin-off from the University of Würzburg and has since raised a total of $24.3 million in funding over three rounds to support its research and development activities. The company targets the healthcare sector, specifically the neurocritical care market, with its therapeutic candidates.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 1998
Headquarters: Würzburg, Germany
Employees: 2
Open positions: None listed
Dealroom signal: 58.6/100
Industry: Health
Sub-industry: BioTechnology, Health Platform
Sector: Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, Digital Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jul 2019	$10M	$42M	Bayern Kapital · Entrepreneurs Fund · Fort Rock Capital · Creathor Ventures	—
LATE VCOther financing	Jan 2016	$22M	$88M	Bayern Kapital · Heidelberg Capital Private Equity · Fort Rock Capital · Entrepreneurs Fund	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Vasopharm website traffic

Latest recorded traffic for Vasopharm is 200 monthly website visits, up 17.6% over the last three months. Vasopharm's team declined 50% over the past year.

Latest monthly visits200 3-month web change+17.6% 1-year team growth-50%

Monthly website visitsDec 2016–Nov 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NANanoPhoriaNon-viral nanoparticle drug delivery platform for cardiovascular treatments	Milan, Italy	Operational	17	$98M	$367M
EBELEM BiotechCreates software products for the medical industry to optimize and test medical treatments	Barcelona, Spain	Operational
RBRiver BioMedicsBiotech company that aims to develop human 3d in vitro 3d human heart tissue for pre-clinical drug testing	Enschede, Netherlands	Operational
ABAxol BioscienceSells live human cell cultures and provides services such as genome editing to researchers	Cambridge, United Kingdom	Acquired
EVEverZomA key asset to the future health of an ageing population	Paris, France	Operational
STSTALICLATranslating precision medicine for Autism Spectrum Disorder	Geneva, Switzerland	Operational
REResistellOffers an alternative to culture-based antibiogram, the gold standard in antibiotic susceptibility testing (AST)	Muttenz, Switzerland	Operational
BMBioTrace MedicalBioTrace Medical, Inc is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs	San Carlos, United States	Operational